Albinism B-BCVA improves in early school years

Article

Albinos experience an improvement in binocular best-corrected visual acuity (B-BCVA).

Albinos experience an improvement in binocular best-corrected visual acuity (B-BCVA), according to an investigation in the Journal of Paediatric Ophthalmology and Strabismus.

The study, headed by Dr Johanna M. Dijkstal, Department of Ophthalmology, University of Minnesota, Minneapolis, Minnesota, USA, involved the investigation of B-BCVA in albino patients. The information recorded included type of albinism, B-BCVA, glasses wear, iris pigment, macular transparency grade and presence or absence of an annular reflex and melanin in the macular. Each patient was visited between the ages of 5.5 and 9 years (Visit A) and 9.5 and 14 years (Visit B) with a gap of at least 2.5 years between visits.

Visit A revealed a mean B-BCVA of 20/84 and Visit B demonstrated a mean B-BCVA of 20/61, meaning B-BCVA improved by 80%. There was no strong correlation between improvement in B-BCVA and glasses wear, iris grade, macular grade, macular melanin, and annular reflex.

However, from Visit A and Visit the team discovered a moderate correlation between B-BCVA and iris grade. The study showed that B-BCVA frequently improves in albinism in the early school years. It is said to be linked to changes in nystagmus, use of precise null point, developmental maturation, and ocular characteristics.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.